KRAS and pancreatic neoplasm: Knockdown of SMYD3 by RNAi has been reported to result in decreased cell proliferation in hepatocellular carcinoma, breast, cervical and esophageal cell lines and also in oncogenic KRAS -driven pancreatic cancer and lung adenocarcinoma cell lines [14–26].